WO1998026078A1 - H mutant alpha-amylase enzymes - Google Patents
H mutant alpha-amylase enzymes Download PDFInfo
- Publication number
- WO1998026078A1 WO1998026078A1 PCT/US1996/019595 US9619595W WO9826078A1 WO 1998026078 A1 WO1998026078 A1 WO 1998026078A1 US 9619595 W US9619595 W US 9619595W WO 9826078 A1 WO9826078 A1 WO 9826078A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- protein
- amino acid
- bacillus
- amylase
- precursor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
- C12N9/2405—Glucanases
- C12N9/2408—Glucanases acting on alpha -1,4-glucosidic bonds
- C12N9/2411—Amylases
- C12N9/2414—Alpha-amylase (3.2.1.1.)
- C12N9/2417—Alpha-amylase (3.2.1.1.) from microbiological source
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/189—Enzymes
-
- C—CHEMISTRY; METALLURGY
- C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
- C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
- C11D3/00—Other compounding ingredients of detergent compositions covered in group C11D1/00
- C11D3/16—Organic compounds
- C11D3/38—Products with no well-defined composition, e.g. natural products
- C11D3/386—Preparations containing enzymes, e.g. protease or amylase
-
- C—CHEMISTRY; METALLURGY
- C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
- C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
- C11D3/00—Other compounding ingredients of detergent compositions covered in group C11D1/00
- C11D3/16—Organic compounds
- C11D3/38—Products with no well-defined composition, e.g. natural products
- C11D3/386—Preparations containing enzymes, e.g. protease or amylase
- C11D3/38627—Preparations containing enzymes, e.g. protease or amylase containing lipase
-
- C—CHEMISTRY; METALLURGY
- C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
- C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
- C11D3/00—Other compounding ingredients of detergent compositions covered in group C11D1/00
- C11D3/16—Organic compounds
- C11D3/38—Products with no well-defined composition, e.g. natural products
- C11D3/386—Preparations containing enzymes, e.g. protease or amylase
- C11D3/38636—Preparations containing enzymes, e.g. protease or amylase containing enzymes other than protease, amylase, lipase, cellulase, oxidase or reductase
-
- C—CHEMISTRY; METALLURGY
- C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
- C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
- C11D3/00—Other compounding ingredients of detergent compositions covered in group C11D1/00
- C11D3/16—Organic compounds
- C11D3/38—Products with no well-defined composition, e.g. natural products
- C11D3/386—Preparations containing enzymes, e.g. protease or amylase
- C11D3/38645—Preparations containing enzymes, e.g. protease or amylase containing cellulase
-
- C—CHEMISTRY; METALLURGY
- C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
- C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
- C11D3/00—Other compounding ingredients of detergent compositions covered in group C11D1/00
- C11D3/16—Organic compounds
- C11D3/38—Products with no well-defined composition, e.g. natural products
- C11D3/386—Preparations containing enzymes, e.g. protease or amylase
- C11D3/38654—Preparations containing enzymes, e.g. protease or amylase containing oxidase or reductase
Definitions
- the present invention is directed to improved proteins, and particularly enzymes, having altered stability characteristics through the recruitment of residues from a less stable homolog or related protein.
- the present invention is particularly directed to novel mutant ⁇ - amylase enzymes derived from B. licheniformis having at least one recruitment from a corresponding residue in B. stearothermophilus and/or B. amyloliquefaciens which differs from the residue in B. licheniformis.
- the resultant ⁇ -amylases exhibit improved stability under adverse conditions.
- ⁇ -Amylases hydrolyze internal ⁇ -1 ,4-glucosidic linkages in starch, largely at random, to produce smaller molecular weight malto-dextrins.
- ⁇ -Amylases are of considerable commercial value, being used in the initial stages (liquefaction) of starch processing; in alcohol production; as cleaning agents in detergent matrices; and in the textile industry for starch desizing.
- ⁇ -Amylases are produced by a wide variety of bacterial, fungal and plant sources including Bacillus and Aspergiilus, with most commercial amylases used in the starch processing industry being produced from bacterial sources such as Bacillus licheniformis, Bacillus amyioliquefaciens, Bacillus subtilis, or Bacillus stearothermophilus.
- Bacillus licheniformis Bacillus amyioliquefaciens
- Bacillus subtilis Bacillus subtilis
- Bacillus stearothermophilus the preferred enzymes in commercial use have been those from Bacillus licheniformis because of their heat stability and performance, at least at neutral and mildly alkaline pH's.
- Amylases derived from related species such as Bacillus amyioliquefaciens, Bacillus subtilis and Bacillus stearothermophilus are generally believed to be considerably less stable under many conditions.
- Variant ⁇ -amylases have been suggested in PCT Publication No. WO 95/10603, which have improved laundry or dishwashing performance and comprise a mutation other than a single mutation at position M 197 in Bacillus licheniformis ⁇ -amylase.
- PCT Publication No. WO 94/02597 a mutant ⁇ -amylase having improved oxidative stability is described wherein one or more methionines are replaced by any amino acid except cysteine or methionine.
- WO 94/18314 a mutant ⁇ -amylase having improved oxidative stability is described wherein one or more of the methionine, tryptophan, cysteine, histidine or tyrosine residues is replaced with a non-oxidizable amino acid.
- PCT Publication No. WO 91/00353 the performance characteristics and problems associated with starch liquefaction with wild type Bacillus licheniformis ⁇ -amylase are approached by genetically engineering the ⁇ -amylase to include the specific substitutions Ala-111-Thr, His- 133-Tyr and/or Thr-149-lle.
- an improved protein comprising an amino acid sequence which has been altered from a precursor amino acid sequence by the substitution or deletion of an amino acid residue which differs from a corresponding amino acid residue in a less stable but homologous protein.
- the improved protein has improved stability properties compared to a protein corresponding to the precursor amino acid sequence.
- the substitution or deletion does not occur at a buried residue but instead at a residue on the surface of the molecule.
- the protein is an enzyme, most preferably an ⁇ -amylase, lipase, cellulase or protease.
- the enzyme is an ⁇ -amylase derived from Bacillus licheniformis and the less stable but homologous protein comprises either or both of the amylases derived from Bacillus amyioliquefaciens or Bacillus stearothermophilus.
- the precursor protein is ⁇ - amylase derived from Bacillus licheniformis and the substituted residues in the improved protein, which differ in both Bacillus stearothermophilus and Bacillus amyioliquefaciens, comprise one or more of A33, A52, N96, H133, S148, A209, A269, A379 and A435, preferably comprising the following specific substitutions which occur naturally in both
- Bacillus stearothermophilus and Bacillus amyioliquefaciens i.e., A33 S, A52 S, N96 Q, H133 Y, S148 N, A209 V, A269 K, A379 S and/or A435 S.
- a method for the production of an improved protein based on a precursor protein comprising: (a) aligning the sequence of the precursor protein with a sequence of a less stable but homologous enzyme and identifying one or more residues which differ between the sequence of the precursor protein and the less stable but homologous enzyme; (b) selecting one or more of the residues identified in step (a) for substitution in the precursor protein; and (c) modifying the precursor protein to incorporate a residue for substitution selected in the step (b).
- the substitution occurs at a residue which is on the surface of the protein and not at a buried residue.
- An advantage of the present invention is that it is possible to produce more stable protein through a simple technique of analyzing the aligned sequences of two homologous but stability differentiated proteins.
- Figure 1 illustrates mutagenic oligonucleotides useful during directed mutagenesis of Asn188 from Bacillus licheniformis ⁇ -amylase.
- bold letters indicate base changes introduced by the oligonucleotide and underlining indicates restriction endonuclease sites introduced by the oligonucleotide.
- Figure 2 illustrates PCR primers used for PCR processing of mutagenic oligonucleotide templates.
- Figure 3 illustrates the DNA sequence of the gene for ⁇ -amylase from Bacillus licheniformis (NCIB 8061) (SEQ ID NO:33) and deduced amino acid sequence of the translation product (SEQ ID NO:41) as described by Gray et al., J. Bacteriology, vol. 166, pp. 635-643 (1986).
- Figure 4 illustrates the amino acid sequence (SEQ ID NO:34) of the mature ⁇ - amylase enzyme from Bacillus licheniformis.
- Figure 5 illustrates an alignment of the primary structures of three Bacillus ⁇ -amylases.
- the Bacillus licheniformis ⁇ -amylase (Am-Lich) (SEQ ID NO:35) is described by Gray et al., J. Bacteriology, vol. 166, pp. 635-643 (1986); the Bacillus amyioliquefaciens ⁇ -amylase (Am-Amylo) (SEQ ID NO:36) is described by Takkinen et al., J. Biol. Chem., vol. 258, pp.
- Em R refers to erythromycin resistance and Rep pTA1060 refers to the origin of replication from plasmid pTA1060.
- Figure 7 illustrates the pBLapr plasmid wherein BL AA refers to Bacillus licheniformis ⁇ -amylase gene; aprE refers to the promoter and signal peptide encoding region of the aprE gene; AmpR refers to the ampicillin resistant gene from pBR322; and CAT refers to the chloramphenicol resistance gene from pC194.
- Figure 8 illustrates the pHP.BL plasmid carrying the gene for Bacillus licheniformis ⁇ - amylase.
- Figure 9 illustrates a schematic of the PCR method used to produce the mutant oligonucleotides corresponding to ⁇ -amylase derived from Bacillus licheniformis.
- Figure 10 illustrates the signal sequence-mature protein junctions in ⁇ -amylase derived from Bacillus licheniformis (SEQ ID NO:38), Bacillus subtilis aprE (SEQ ID NO: 39) and Bacillus licheniformis in pBLapr (SEQ ID NO:40).
- “Expression vector” means a DNA construct comprising a DNA sequence which is operably linked to a suitable control sequence capable of effecting the expression of said DNA in a suitable host.
- control sequences may include a promoter to effect transcription, an optional operator sequence to control such transcription, a sequence encoding suitable mRNA ribosome-binding sites, and sequences which control termination of transcription and translation.
- a preferred promoter is the Bacillus subtilis aprE promoter.
- the vector may be a plasmid, a phage particle, or simply a potential genomic insert. Once transformed into a suitable host, the vector may replicate and function independently of the host genome, or may, in some instances, integrate into the genome itself. While plasmid and vector are sometimes used interchangeably as the plasmid is the most commonly used form of vector at present, the invention is intended to include such other forms of expression vectors which serve equivalent functions and which are, or become, known in the art.
- “Host strain” or “host cell” means a suitable host for an expression vector comprising DNA encoding a protein according to the present invention.
- Host cells useful in the present invention are generally procaryotic or eucaryotic hosts, including any transformable microorganism in which the expression of a given protein according to the present invention can be achieved.
- One of skill in the art will be familiar with the appropriate expression and secretion machinery, including the appropriate host cell, for use with a specific protein.
- host strains of the same species or genus from which the particular protein is derived are suitable, for example with ⁇ -amylase derived from Bacillus, a suitable host cell would be a Bacillus strain.
- an ⁇ -amylase negative Bacillus strain (genes deleted) and/or an ⁇ -amylase and protease deleted Bacillus strain (AamyE, ⁇ apr, ⁇ np ⁇ is preferably used.
- Host cells are transformed or transfected with vectors constructed using recombinant DNA techniques. Such transformed host cells are capable of either replicating vectors encoding the protein and its variants (mutants) or expressing the desired protein.
- "Recombinant protein” means a protein in which the DNA sequence encoding the naturally occurring or precursor protein is modified to produce a mutant DNA sequence which encodes the substitution, insertion or deletion of one or more amino acids in the protein sequence compared to the naturally occurring or precursor protein.
- precursor protein refers not to an immediate precursor in terms of a chemical reaction, but instead to a parent protein from which the modification is modeled. Accordingly, while it is the precursor which defines the modification, the actual alteration or modification will have its basis in an alteration within the DNA which encodes the precursor, which DNA is then transformed, expressed and the protein product secreted which incorporates the modification.
- the improved protein according to the present invention comprises an amino acid sequence which is derived from the amino acid sequence of a precursor protein.
- the precursor protein may be a naturally occurring protein or a recombinant protein.
- the amino acid sequence of the improved protein is derived from the precursor protein's amino acid sequence by the substitution, deletion or insertion of one or more amino acids of the precursor amino acid sequence.
- Such modification is generally of the precursor DNA sequence which encodes the amino acid sequence of the precursor proteins rather than manipulation of the precursor protein perse. Suitable methods for such manipulation of the precursor DNA sequence include methods disclosed herein and in commonly owned U.S. Patent Nos. 4,760,025 and 5,185,258, incorporated herein by reference.
- a protein is modified as follows.
- the protein is referenced to a homologous protein for differences in sequence. For example, it is possible to line up the sequences of two related proteins according to well known sequence alignment techniques and determine conserved (i.e., identical) positions as well as the positions at which the two proteins differ.
- sequence alignment techniques For example, it is possible to line up the sequences of two related proteins according to well known sequence alignment techniques and determine conserved (i.e., identical) positions as well as the positions at which the two proteins differ.
- conserved i.e., identical
- it has surprisingly and unexpectedly been found that by referencing the target protein against a less stable protein and identifying and selecting certain residues which differ from the less stable protein for modification in the target protein, advantageous improvements in stability may be obtained.
- the two proteins have comparable activity or function and be substantially homologous. By comparable activity, the proteins should have similar biological activity, function, catalytic activity or such other criteria as are commonly used to classify a specific protein.
- Substantially homologous means that the proteins have a significant level of conserved, i.e., identical, amino acids such that their sequences can be meaningfully aligned and major structural, functional or catalytic sites defined.
- the two proteins Preferably, have a sequence identity of at least 60%, more preferably 65% sequence identity, and most preferably 80% sequence identity.
- the improved protein of the invention should have stability which is at least 50% of the precursor protein, more preferably at least 70%, and most preferably at least 90% of the precursor protein under any given set of circumstances, yet having improved stability under other conditions.
- an improved protein which has a stability of at least 50% of the precursor enzyme under high temperature but which has improved stability under oxidative conditions would be within the scope of the invention.
- the stability of the improved protein is improved with respect to the precursor protein in the presence of oxidants and high temperature.
- the protein comprises an enzyme.
- the enzyme may comprise any enzyme in the five major enzyme classifications of hydrolase, oxidoreductase, transferase, lyase or ligase.
- Specific examples of enzymes which may benefit from the present invention include amylase, lipase, cellulase, protease, hemicellulase, glucoamylase, esterase, lactase, polygalacturonase, ⁇ -galactosidase, ligninase, oxidase, peroxidase, glucose isomerase or any enzyme for which closely related and less stable homologs exist.
- ⁇ -Amylase will be illustrated as exemplary of the inventive process and compositions.
- ⁇ -Amylase as used herein means an enzymatic activity which cleaves or hydrolyzes the ⁇ (1-4)glycosidic bond, e.g., that in starch, amylopectin or amylose polymers.
- ⁇ -Amylase includes naturally occurring ⁇ -amylases as well as recombinant ⁇ -amylases.
- Preferred ⁇ - amylases in the present invention are those derived from Bacillus sp., particularly those from Bacillus licheniformis, Bacillus amyioliquefaciens or Bacillus stearothermophilus, as well as fungal ⁇ -amylases such as those derived from Aspergiilus (i.e., A.
- the ⁇ -amylases according to the present invention are derived from a precursor ⁇ -amylase.
- the precursor ⁇ -amylase is produced by any source capable of producing ⁇ - amylase. Suitable sources of ⁇ -amylases are prokaryotic or eukaryotic organisms, including fungi, bacteria, plants or animals.
- the precursor ⁇ -amylase is produced by a Bacillus; more preferably, by Bacillus licheniformis, Bacillus amyioliquefaciens or Bacillus stearothermophilus; most preferably, the precursor ⁇ -amylase is derived from Bacillus licheniformis.
- Sequence alignments have also been used to map the relationship between Bacillus endo-amylases (Feng et al., J. Molec. Evol., vol. 35, pp. 351-360 (1987)).
- the relative sequence homology between Bacillus stearothermophilus and Bacillus licheniformis amylase is about 66% and that between Bacillus licheniformis and Bacillus amyioliquefaciens amylases is about 81 %, as determined by Holm et al., Protein Engineering, vol. 3, No. 3, pp. 181-191 (1990).
- the amino acid sequence of a precursor ⁇ -amylase is directly compared to the Bacillus licheniformis ⁇ -amyiase primary sequence and particularly to a set of residues known to be invariant to all ⁇ -amylases for which sequences are known (see e.g., Figure 7). It is possible also to determine equivalent residues by tertiary structure analysis of the crystal structures reported for porcine pancreatic ⁇ -amylase (Buisson et al., EMBO Journal, vol. 6, pp. 3909-3916 (1987); Qian et al.,
- ⁇ -amylases from Bacillus licheniformis, Bacillus stearothermophilus, Bacillus amyioliquefaciens and Bacillus subtilis all bear a significant degree of homology.
- high temperature excess of 90 ' C
- low pH pH 4-6
- low calcium ⁇ - amylase derived from Bacillus licheniformis provides the most acceptable performance.
- Bacillus licheniformis ⁇ -amylase is susceptible to undesirable instability under liquefaction conditions making a more stable alternative desirable.
- the substituted residue is actually an identical residue as that which exists in ⁇ -amylase from either B. stearothermophilus or B. amyioliquefaciens. More preferably, the substituted residue corresponds to a position in which the same residue exists in both ⁇ -amylase from B. stearothermophilus and B. amyioliquefaciens.
- Residues specifically identified herein for replacement in Bacillus licheniformis are those which differ from residues in a corresponding position in Bacillus amyioliquefaciens and/or Bacillus stearothermophilus, and particularly A33, A52, S85, N96, H133, S148, A209, A269, A379 and A435. While specific preferred replacements for these residues are selected from those present in both Bacillus amyioliquefaciens and Bacillus stearothermophilus and correspond to A33S, A52S, N96Q, H133Y, S148N, A209V, A269K, A379S and/or A435S.
- the A85D mutation which is recruited only from Bacillus amyioliquefaciens also provides a stability benefit.
- the above residues may be altered in combination with other modifications which provide a performance benefit.
- the above residues are in combination with mutations at a residue corresponding to any of M15, N188 and/or M197 and particularly at M15T, N188S, and/or M197T in Bacillus licheniformis. Any of the modifications identified herein as in accordance with the invention in combination with a mutant corresponding to M15T/H133Y/N188S/A209V in Bacillus licheniformis will have a particularly improved stability profile.
- the improved proteins according to the present invention exhibit improved performance characteristics which make those proteins particularly useful in various applications for which the proteins are commonly used and for which improved stability is desired.
- enzymes including ⁇ -amylases, according to the present invention will exhibit improved thermostability, improved pH stability and/or improved oxidative stability.
- Enhanced thermostability will be useful in extending the shelf life of products which incorporate them and for applications at high temperatures.
- Enhanced oxidative stability or improved performance is particularly desirable in cleaning products, and for extending the shelf life of the enzyme in the presence of bleach, perborate, percarbonate or peracids used in such cleaning products.
- An ⁇ -amylase of the present invention is especially useful in starch processing and particularly in starch liquefaction wherein oxidative and thermal stability are particularly important.
- An additional embodiment of the present invention comprises DNA encoding a protein according to the present invention and expression vectors comprising such DNA.
- the DNA sequences may be expressed by operably linking them to an expression control sequence in an appropriate expression vector and employing that expression vector to transform an appropriate host according to well known techniques.
- a wide variety of host/expression vector combinations may be employed in expressing the DNA sequences of this invention.
- Useful expression vectors include segments of chromosomal, non-chromosomal and synthetic DNA sequences, such as the various known plasmids and phages useful for this purpose.
- any of a wide variety of expression control sequences are generally used in these vectors.
- a preferred expression control sequence for Bacillus transformants is the aprE signal peptide derived from Bacillus subtilis.
- a wide variety of host cells are also useful in expressing the DNA sequences of this invention. These hosts may include well known eukaryotic and prokaryotic hosts, such as strains of E. coli, Pseudomonas, Bacillus, Streptomyces, various fungi, yeast and animal cells. Preferably, the host expresses the protein of the present invention extracellularly to facilitate purification and downstream processing. Expression and purification of the improved protein of the invention may be effected through art-recognized means for carrying out such processes.
- the ⁇ -amylase gene shown in Figure 3 was cloned from Bacillus licheniformis NCIB8061 (Gray et al., J. Bacteriology, vol. 166, pp. 635-643 (1986)).
- a synthetic terminator was added between the Bell and Sstl sites using a synthetic oligonucleotide cassette of the form:
- the pBLapr plasmid was constructed carrying the gene for the Bacillus licheniformis ⁇ -amylase. As illustrated in Figure 7, pBLapr comprises a 6.1 kb plasmid including the ampicillin resistance gene from pBR322 and the chloramphenicol resistance gene from pC194, the aprE promoter and the gene encoding for the Bacillus licheniformis ⁇ -amylase ("BL AA").
- the aprE promoter was constructed from a 660bp Hindlll-Pstl fragment encoding for the promoter and signal sequence of the Bacillus subtilis alkaline protease.
- the Pstl site was removed, and an Sfil site added close to the aprE/BL AA junction.
- the BL AA gene comprises the 1720 bp Pstl-Sstl fragment described above.
- pBLapr was constructed with an Sfil site adjacent to the 5' end of the start of the coding sequence for the mature amylase gene. Specifically, the 5' end of the pBLapr construction was subcloned on an EcoRI-Sstll fragment from pBLapr into M13BM20 (Boehringer Mannheim) to obtain a coding-strand template for the mutagenic oligonucleotide below:
- This primer introduced an Sfil site (indicated by underlining) which allowed correct forms to be screened for by the presence of this unique restriction site. Subcloning the EcoRI-Sstll fragment back into the pBLapr vector gave a version of the plasmid containing an Sfil site.
- Plasmid pHP13 (Haima et al., Mol. Gen. Genet., vol. 209, pp. 335-342 (1987)) ( Figure 6) was digested with restriction enzymes EcoRI and Hindlll and the resulting vector purified on a polyacrymide gel and then eluted. Plasmid pBLapr was digested with Hindlll, Asp718 and in a separate incubation with Asp718, EcoRI and gel purified.
- Step (1) The mutagenic primers were used as templates for the PCR primers PCR A+ and PCR B- resulting in a lengthened (61 bp) double stranded DNA. Each contained a different amino acid replacement at position 188, and all except N188M contained a different restriction site. Initially the PCR primers were annealed at 35 ⁇ C for five minutes followed by a one minute DNA extension with taq polymerase at 75°C. The double stranded DNA was then melted at 95°C for one minute, followed by the annealing and extension steps. Melting, annealing and extension continued for a total of 30 cycles. Step (2): DNA upstream and downstream of position 188 were made in separate PCR reactions.
- the template was pBLapr, and the PCR primers were LAAfs ⁇ (SEQ ID NO:27) and PCR A- (SEQ ID NO:24) for upstream; and PCR B+ (SEQ ID NO:25) and PCR Cla-Sall (SEQ ID NO:28) for downstream DNA.
- the DNA was melted at 95°C for one minute, annealed at 45°C for three minutes and elongated at 68°C for 3 minutes.
- the upstream portion is 290 bp and downstream is 498 bp. This procedure was repeated for 18 cycles using pfu polymerase.
- the same PCR procedure was used in steps (3) and (4).
- Step (3) The upstream portion of DNA described in step (2) was attached to the double stranded mutagenic primers described in step (1).
- Primers LAAfs ⁇ SEQ ID NO:27
- PCR B- SEQ ID NO:26
- Step (4) The downstream portions of DNA described in Step (2) and the product of Step (3) were attached to give the final product. A 24 bp overlap between the two PCR products allows for the attachment. Primers used were LAAfs ⁇ (SEQ ID NO:27) and PCR Clal-Sall (SEQ ID NO:28).
- Step (5) Unique restriction sites, Asp718 and BssHII, are located upstream and downstream, respectively, of the 188 site.
- the final PCR product is digested with Asp718 and BssHII, the 333 bp fragment isolated by polyacrylamide gel electrophoresis and subcloned into the pHP.BL vector to obtain pHP.N188X.
- PCR primers A+ and A- correspond to base pairs 784-807.
- PCR primers B+ and B- correspond to base pairs 821-844.
- the 5' end of PCR primer LAAfs ⁇ corresponds to base pair 518.
- the 5' end of PCR primer PCR Clal-Sall corresponds to base pair 1317.
- the Asp718 site corresponds to base pair 724.
- the BssHII site corresponds to base pair 1053.
- a pBLapr plasmid having threonine substituted for methionine at amino acid 15 was constructed according to U.S. Patent Application Serial No. 08/194,664 (PCT Publication No. WO 94/18314).
- This plasmid (pBLaprM15T) was digested with Sfil and Asp718, and the 477 base pair fragment subcloned into pHP.BL to create pHP.M15T.
- pHP.M15T was digested with Asp718 and BssHII, gel purified and eluted from the gel.
- the 333 base pair fragment comprising Asp718 to BssHII and the fragment from pHP.N188S were then subcloned into pHP.M15T to give plasmid pHP.M15T/N188S.
- the plasmid pHP.M15L/N188Y was constructed.
- ⁇ -Amylase was expressed in Bacillus subtilis after transformation with the plasmids described in Examples 1-3.
- pHP13 is a plasmid able to replicate in E. coli and in Bacillus subtilis. Plasmids containing different variants were constructed using E. coli strain MM294, the plasmids isolated and then transformed into Bacillus subtilis as described in Anagnostopoulos et al., J. Bacter., vol. 81 , pp. 741-746 (1961). The Bacillus strain had been deleted for two proteases ( ⁇ apr, ⁇ npr) (see e.g., Ferrari et al., U.S. Patent No.
- Soluble Substrate Assay A rate assay was developed based on an end-point assay kit supplied by Megazyme (Aust.) Pty. Ltd. A vial of substrate (p-nitrophenyl maltoheptaoside, BPNPG7) was dissolved in 10ml of sterile water followed by a 1 :4 dilution in assay buffer (50mM maleate buffer, pH 6.7, 5mM calcium chloride, 0.002% Tween20). Assays were performed by adding 10 ⁇ l of amylase to 790 ⁇ l of the substrate in a cuvette at 25°C. Rates of hydrolysis were measured as the rate of change of absorbance at 410nm, after a delay of 75 seconds.
- the assay was linear up to rates of 0.2 absorption units/min.
- ⁇ -Amylase protein concentration was measured using the standard Bio-Rad Assay (Bio-Rad Laboratories) based on the method of Bradford, Anal. Biochem., vol. 72, p. 248 (1976) using bovine serum albumin standards.
- ⁇ -Amyiase activity on starch was determined through an assay which depends on the ability of starch to form a blue colored complex with iodine and the disappearance of this color when starch is hydrolyzed to shorter dextrin molecules.
- the ⁇ -amylase activity was defined in terms of the digestion time required to produce a color change denoting a definite state of dextrination of the starch. Reagents used were as follows:
- Phosphate buffer- Potassium dihydrogen phosphate (340 g) and sodium hydroxide (25.3 g) were dissolved in water and diluted to ⁇ two liters.
- the buffer was cooled to room temperature and the pH was adjusted to 6.2 ⁇ 0.1.
- the buffer was diluted to two liters in a volumetric flask.
- Starch substrate Ten grams (dry substance) of soluble lintner starch were suspended in 50 ml of water and washed into ⁇ 300 ml of boiling water. The suspension was again brought to boiling and was boiled for five minutes with constant stirring. The starch solution was cooled with constant stirring to room temperature and 125 ml of phosphate buffer was added. The solution was diluted to 500 ml with water. The starch substrate was made fresh daily.
- Stock iodine solution - Iodine crystals (5.5 g) and potassium iodide (11.0 g) were dissolved in water and were volumetrically diluted to 250 ml. The solution was kept from light. Dilute iodine solution - Potassium iodide (20 g) and two ml of stock iodine solution were dissolved in water and diluted volumetrically to 500 ml. The solution was made fresh daily.
- Enzyme diluting solution - Calcium chloride (11.1 g) was dissolved in four liters of water. Water used for all reagents was either distilled or deionized. An ⁇ -amylase sample was diluted to between 10-15 LU/ml (as defined below) with enzyme diluting solution. For many commercial ⁇ -amylase preparations a suitable dilution was found to be 2000 fold. Five milliliter aliquots of dilute iodine solution were dispensed into 13 x 100 mm test tubes and 10 ml of starch substrate was placed in a 23 x 200 mm test tube. All tubes were placed in the 30°C water bath.
- a Hellige comparator equipped with a special ⁇ -amylase color disc (catalog number 620-s5) was used to make readings.
- Five milliliters of diluted enzyme (also at 30°C) were mixed with the starch substrate and timing was begun. At appropriate time intervals, for example one minute intervals early in the reaction and 15 second intervals later in the reaction, one ml aliquots of the enzyme- substrate mixture were transferred to a tube containing the dilute iodine solution.
- the starch iodine solution was mixed and transferred to a 13 mm precision square tube and the color was compared with the standard ⁇ -amylase color disc in the Hellige comparator. When the time of the end point was approached, samples were taken at 0.25 minute intervals.
- V volume of enzyme (5 ml or grams)
- t dextrinization time (minutes)
- D dilution factordilution volume divided by ml or g of enzyme diluted.
- Mutant alpha-amylases were prepared having substitutions at one or more of five positions for which corresponding residues in both Bacillus stearothermophilus and Bacillus amyioliquefaciens were identical: A33S, A52S, N96Q S148N, A379S in combination with M15T/H133Y/N1885/A209V and compared with a mutant comprising only the
- the mutation S85D which represents a recruitment from the Bacillus amyioliquefaciens.
- the mutations were prepared according to the procedures provided in Examples 1-4 except that appropriate PCR primers were provided to effect the desired mutations. Thermal inactivation rates for the various mutants were measured according to the following procedure. Amylase stock solutions were dialysed extensively into 20 mM ammonium acetate, 4 mM CaCI 2 pH 6.5.
- this stock was diluted >50fold into a solution designed to induce rapid inactivation of wild type amylase: 50mM ammonium acetate, 5mM CaCI 2 , 0.02% Tween 20 and a pH of 4.9, or 4.8 to a final concentration of between 30 and 50 ⁇ g/ml.
- Six 100 ⁇ l aliquots were put into Eppendorf tubes and placed into a water bath at either 82 ' C or 83 ' C.
- the Eppendorf tubes were removed at regular, measured intervals of between 30 seconds and 5 minutes and placed on ice to stop the inactivation.
- the residual activity was assayed using a soluble substrate as described in Example 5.
- the natural log of the activity was plotted against time of incubation, and the rate constant for inactivation obtained from the slope of the straight line. The half-life was calculated as fn(2) divided by the rate constant. Results for various mutants are provided in Tables 1-4.
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Health & Medical Sciences (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Polymers & Plastics (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Animal Husbandry (AREA)
- Medicinal Chemistry (AREA)
- Food Science & Technology (AREA)
- Enzymes And Modification Thereof (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Detergent Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Cosmetics (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
Claims
Priority Applications (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE69634640T DE69634640T2 (en) | 1996-12-09 | 1996-12-09 | MUTATED ALPHA-AMYLASE ENZYME WITH INCREASED STABILITY |
| DK96945189T DK0942994T3 (en) | 1996-12-09 | 1996-12-09 | H-mutant alpha-amylase enzymes |
| JP52659698A JP4253041B2 (en) | 1996-12-09 | 1996-12-09 | Protein with improved stability |
| AT96945189T ATE293696T1 (en) | 1996-12-09 | 1996-12-09 | MUTATED ALPHA-AMYLASE ENZYMES WITH INCREASED STABILITY |
| PCT/US1996/019595 WO1998026078A1 (en) | 1996-12-09 | 1996-12-09 | H mutant alpha-amylase enzymes |
| EP96945189A EP0942994B1 (en) | 1996-12-09 | 1996-12-09 | H mutant alpha-amylase enzymes |
| CA2274806A CA2274806C (en) | 1996-12-09 | 1996-12-09 | H mutant alpha-amylase enzymes |
| AU14614/97A AU1461497A (en) | 1996-12-09 | 1996-12-09 | Proteins Having Increased Stability |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US1996/019595 WO1998026078A1 (en) | 1996-12-09 | 1996-12-09 | H mutant alpha-amylase enzymes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO1998026078A1 true WO1998026078A1 (en) | 1998-06-18 |
Family
ID=22256262
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US1996/019595 Ceased WO1998026078A1 (en) | 1996-12-09 | 1996-12-09 | H mutant alpha-amylase enzymes |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP0942994B1 (en) |
| JP (1) | JP4253041B2 (en) |
| AT (1) | ATE293696T1 (en) |
| AU (1) | AU1461497A (en) |
| CA (1) | CA2274806C (en) |
| DE (1) | DE69634640T2 (en) |
| WO (1) | WO1998026078A1 (en) |
Cited By (90)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999009183A1 (en) * | 1997-08-19 | 1999-02-25 | Genencor International, Inc. | MUTANT α-AMYLASE COMPRISING MODIFICATION AT RESIDUES CORRESPONDING TO A210, H405 AND/OR T412 IN $i(BACILLUS LICHENIFORMIS) |
| WO2000077193A1 (en) * | 1999-06-10 | 2000-12-21 | Rijksuniversiteit Groningen | Enzyme selection |
| WO2001047956A3 (en) * | 1999-12-23 | 2002-02-14 | Genencor Int | Method for obtaining proteins having improved functional characteristics |
| US7153818B2 (en) | 2000-07-28 | 2006-12-26 | Henkel Kgaa | Amylolytic enzyme extracted from bacillus sp. A 7-7 (DSM 12368) and washing and cleaning agents containing this novel amylolytic enzyme |
| EP1676913A3 (en) * | 1998-11-16 | 2007-08-29 | Novozymes A/S | Alpha-amylase variants |
| EP1818396A3 (en) * | 1999-03-30 | 2007-12-19 | Novozymes A/S | Alpha-Amylase variants |
| WO2007144856A3 (en) * | 2006-06-16 | 2008-07-24 | Procter & Gamble | Cleaning and / or treatment compositions comprising mutant alpha-amylases |
| US7601527B2 (en) | 1998-11-16 | 2009-10-13 | Novozymes A/S | α-amylase variants |
| US7713723B1 (en) | 2000-08-01 | 2010-05-11 | Novozymes A/S | Alpha-amylase mutants with altered properties |
| US7867746B2 (en) | 1999-03-30 | 2011-01-11 | Novozymes A/S | Alpha-amylase variants |
| JP2011087582A (en) * | 1998-12-18 | 2011-05-06 | Danisco Us Inc | Novel variant egiii-like cellulase composition |
| US8080401B2 (en) | 2004-10-01 | 2011-12-20 | Henkel Ag & Co. Kgaa | Alpha-amylase variants having an elevated solvent stability, method for the production thereof and detergents and cleansers containing these alpha-amylase variants |
| WO2012004759A3 (en) * | 2010-07-08 | 2012-11-01 | Dupont Nutrition Biosciences Aps | Method for identifying a pepsin resistant alpha amylase |
| US8323946B2 (en) | 1995-02-03 | 2012-12-04 | Novozymes A/S | Alpha-amylase mutants |
| WO2014194034A2 (en) | 2013-05-29 | 2014-12-04 | Danisco Us Inc. | Novel metalloproteases |
| WO2014194032A1 (en) | 2013-05-29 | 2014-12-04 | Danisco Us Inc. | Novel metalloproteases |
| WO2014194054A1 (en) | 2013-05-29 | 2014-12-04 | Danisco Us Inc. | Novel metalloproteases |
| WO2014194117A2 (en) | 2013-05-29 | 2014-12-04 | Danisco Us Inc. | Novel metalloproteases |
| WO2014150600A3 (en) * | 2013-03-15 | 2015-05-28 | Angelica Therapeutics, Inc. | Modified toxins |
| WO2015089441A1 (en) | 2013-12-13 | 2015-06-18 | Danisco Us Inc. | Serine proteases of bacillus species |
| WO2015089447A1 (en) | 2013-12-13 | 2015-06-18 | Danisco Us Inc. | Serine proteases of the bacillus gibsonii-clade |
| WO2015095358A1 (en) | 2013-12-18 | 2015-06-25 | E. I. Du Pont De Nemours And Company | Cationic poly alpha-1,3-glucan ethers |
| EP1597363B1 (en) * | 2003-02-26 | 2015-07-15 | Danisco US Inc. | Amylases producing an altered immunogenic response and methods of making and using the same |
| WO2015123323A1 (en) | 2014-02-14 | 2015-08-20 | E. I. Du Pont De Nemours And Company | Poly-alpha-1,3-1,6-glucans for viscosity modification |
| WO2015138283A1 (en) | 2014-03-11 | 2015-09-17 | E. I. Du Pont De Nemours And Company | Oxidized poly alpha-1,3-glucan as detergent builder |
| WO2015195777A1 (en) | 2014-06-19 | 2015-12-23 | E. I. Du Pont De Nemours And Company | Compositions containing one or more poly alpha-1,3-glucan ether compounds |
| WO2015195960A1 (en) | 2014-06-19 | 2015-12-23 | E. I. Du Pont De Nemours And Company | Compositions containing one or more poly alpha-1,3-glucan ether compounds |
| WO2016061438A1 (en) | 2014-10-17 | 2016-04-21 | Danisco Us Inc. | Serine proteases of bacillus species |
| WO2016069548A2 (en) | 2014-10-27 | 2016-05-06 | Danisco Us Inc. | Serine proteases |
| WO2016069544A1 (en) | 2014-10-27 | 2016-05-06 | Danisco Us Inc. | Serine proteases |
| WO2016069557A1 (en) | 2014-10-27 | 2016-05-06 | Danisco Us Inc. | Serine proteases of bacillus species |
| WO2016069569A2 (en) | 2014-10-27 | 2016-05-06 | Danisco Us Inc. | Serine proteases |
| WO2016069552A1 (en) | 2014-10-27 | 2016-05-06 | Danisco Us Inc. | Serine proteases |
| WO2016106011A1 (en) | 2014-12-23 | 2016-06-30 | E. I. Du Pont De Nemours And Company | Enzymatically produced cellulose |
| WO2016201069A1 (en) | 2015-06-09 | 2016-12-15 | Danisco Us Inc | Low-density enzyme-containing particles |
| WO2016201040A1 (en) | 2015-06-09 | 2016-12-15 | Danisco Us Inc. | Water-triggered enzyme suspension |
| WO2016201044A1 (en) | 2015-06-09 | 2016-12-15 | Danisco Us Inc | Osmotic burst encapsulates |
| WO2016205755A1 (en) | 2015-06-17 | 2016-12-22 | Danisco Us Inc. | Bacillus gibsonii-clade serine proteases |
| WO2017079751A1 (en) | 2015-11-05 | 2017-05-11 | Danisco Us Inc | Paenibacillus sp. mannanases |
| WO2017079756A1 (en) | 2015-11-05 | 2017-05-11 | Danisco Us Inc | Paenibacillus and bacillus spp. mannanases |
| WO2017083226A1 (en) | 2015-11-13 | 2017-05-18 | E. I. Du Pont De Nemours And Company | Glucan fiber compositions for use in laundry care and fabric care |
| WO2017083228A1 (en) | 2015-11-13 | 2017-05-18 | E. I. Du Pont De Nemours And Company | Glucan fiber compositions for use in laundry care and fabric care |
| WO2017083229A1 (en) | 2015-11-13 | 2017-05-18 | E. I. Du Pont De Nemours And Company | Glucan fiber compositions for use in laundry care and fabric care |
| WO2017106676A1 (en) | 2015-12-18 | 2017-06-22 | Danisco Us Inc | Polypeptides with endoglucanase activity and uses thereof |
| WO2017192300A1 (en) | 2016-05-05 | 2017-11-09 | Danisco Us Inc | Protease variants and uses thereof |
| WO2017192692A1 (en) | 2016-05-03 | 2017-11-09 | Danisco Us Inc | Protease variants and uses thereof |
| WO2017210295A1 (en) | 2016-05-31 | 2017-12-07 | Danisco Us Inc. | Protease variants and uses thereof |
| WO2017219011A1 (en) | 2016-06-17 | 2017-12-21 | Danisco Us Inc | Protease variants and uses thereof |
| WO2018085524A2 (en) | 2016-11-07 | 2018-05-11 | Danisco Us Inc | Laundry detergent composition |
| WO2018118917A1 (en) | 2016-12-21 | 2018-06-28 | Danisco Us Inc. | Protease variants and uses thereof |
| WO2018118950A1 (en) | 2016-12-21 | 2018-06-28 | Danisco Us Inc. | Bacillus gibsonii-clade serine proteases |
| WO2018169750A1 (en) | 2017-03-15 | 2018-09-20 | Danisco Us Inc | Trypsin-like serine proteases and uses thereof |
| WO2018183662A1 (en) | 2017-03-31 | 2018-10-04 | Danisco Us Inc | Delayed release enzyme formulations for bleach-containing detergents |
| WO2019006077A1 (en) | 2017-06-30 | 2019-01-03 | Danisco Us Inc | Low-agglomeration, enzyme-containing particles |
| WO2019108599A1 (en) | 2017-11-29 | 2019-06-06 | Danisco Us Inc | Subtilisin variants having improved stability |
| WO2019125683A1 (en) | 2017-12-21 | 2019-06-27 | Danisco Us Inc | Enzyme-containing, hot-melt granules comprising a thermotolerant desiccant |
| WO2019156670A1 (en) | 2018-02-08 | 2019-08-15 | Danisco Us Inc. | Thermally-resistant wax matrix particles for enzyme encapsulation |
| WO2019245705A1 (en) | 2018-06-19 | 2019-12-26 | Danisco Us Inc | Subtilisin variants |
| WO2019245704A1 (en) | 2018-06-19 | 2019-12-26 | Danisco Us Inc | Subtilisin variants |
| EP3587569A1 (en) | 2014-03-21 | 2020-01-01 | Danisco US Inc. | Serine proteases of bacillus species |
| WO2020047215A1 (en) | 2018-08-30 | 2020-03-05 | Danisco Us Inc | Enzyme-containing granules |
| WO2020068486A1 (en) | 2018-09-27 | 2020-04-02 | Danisco Us Inc | Compositions for medical instrument cleaning |
| WO2020112599A1 (en) | 2018-11-28 | 2020-06-04 | Danisco Us Inc | Subtilisin variants having improved stability |
| WO2020242858A1 (en) | 2019-05-24 | 2020-12-03 | Danisco Us Inc | Subtilisin variants and methods of use |
| WO2020247582A1 (en) | 2019-06-06 | 2020-12-10 | Danisco Us Inc | Methods and compositions for cleaning |
| EP3872174A1 (en) | 2015-05-13 | 2021-09-01 | Danisco US Inc. | Aprl-clade protease variants and uses thereof |
| WO2022047149A1 (en) | 2020-08-27 | 2022-03-03 | Danisco Us Inc | Enzymes and enzyme compositions for cleaning |
| WO2022165107A1 (en) | 2021-01-29 | 2022-08-04 | Danisco Us Inc | Compositions for cleaning and methods related thereto |
| WO2023278297A1 (en) | 2021-06-30 | 2023-01-05 | Danisco Us Inc | Variant lipases and uses thereof |
| WO2023034486A2 (en) | 2021-09-03 | 2023-03-09 | Danisco Us Inc. | Laundry compositions for cleaning |
| WO2023039270A2 (en) | 2021-09-13 | 2023-03-16 | Danisco Us Inc. | Bioactive-containing granules |
| EP4163305A1 (en) | 2013-12-16 | 2023-04-12 | Nutrition & Biosciences USA 4, Inc. | Use of poly alpha-1,3-glucan ethers as viscosity modifiers |
| WO2023114939A2 (en) | 2021-12-16 | 2023-06-22 | Danisco Us Inc. | Subtilisin variants and methods of use |
| WO2023114932A2 (en) | 2021-12-16 | 2023-06-22 | Danisco Us Inc. | Subtilisin variants and methods of use |
| WO2023114936A2 (en) | 2021-12-16 | 2023-06-22 | Danisco Us Inc. | Subtilisin variants and methods of use |
| WO2023168234A1 (en) | 2022-03-01 | 2023-09-07 | Danisco Us Inc. | Enzymes and enzyme compositions for cleaning |
| WO2023225459A2 (en) | 2022-05-14 | 2023-11-23 | Novozymes A/S | Compositions and methods for preventing, treating, supressing and/or eliminating phytopathogenic infestations and infections |
| WO2023250301A1 (en) | 2022-06-21 | 2023-12-28 | Danisco Us Inc. | Methods and compositions for cleaning comprising a polypeptide having thermolysin activity |
| US11920170B2 (en) | 2015-12-09 | 2024-03-05 | Danisco Us Inc. | Alpha-amylase combinatorial variants |
| WO2024050343A1 (en) | 2022-09-02 | 2024-03-07 | Danisco Us Inc. | Subtilisin variants and methods related thereto |
| WO2024050339A1 (en) | 2022-09-02 | 2024-03-07 | Danisco Us Inc. | Mannanase variants and methods of use |
| WO2024050346A1 (en) | 2022-09-02 | 2024-03-07 | Danisco Us Inc. | Detergent compositions and methods related thereto |
| WO2024102698A1 (en) | 2022-11-09 | 2024-05-16 | Danisco Us Inc. | Subtilisin variants and methods of use |
| WO2024163584A1 (en) | 2023-02-01 | 2024-08-08 | Danisco Us Inc. | Subtilisin variants and methods of use |
| WO2024186819A1 (en) | 2023-03-06 | 2024-09-12 | Danisco Us Inc. | Subtilisin variants and methods of use |
| WO2024191711A1 (en) | 2023-03-16 | 2024-09-19 | Nutrition & Biosciences USA 4, Inc. | Brevibacillus fermentate extracts for cleaning and malodor control and use thereof |
| WO2025071996A1 (en) | 2023-09-28 | 2025-04-03 | Danisco Us Inc. | Variant cutinase enzymes with improved solubility and uses thereof |
| WO2025085351A1 (en) | 2023-10-20 | 2025-04-24 | Danisco Us Inc. | Subtilisin variants and methods of use |
| WO2026024921A1 (en) | 2024-07-25 | 2026-01-29 | The Procter & Gamble Company | Detergent composition comprising a subtilisin variant and methods of use |
| WO2026050315A1 (en) | 2024-08-29 | 2026-03-05 | Danisco Us Inc. | Subtilisin variants and methods of use |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1995010603A1 (en) * | 1993-10-08 | 1995-04-20 | Novo Nordisk A/S | Amylase variants |
| WO1995035382A2 (en) * | 1994-06-17 | 1995-12-28 | Genecor International Inc. | NOVEL AMYLOLYTIC ENZYMES DERIVED FROM THE B. LICHENIFORMIS α-AMYLASE, HAVING IMPROVED CHARACTERISTICS |
| WO1996023874A1 (en) * | 1995-02-03 | 1996-08-08 | Novo Nordisk A/S | A method of designing alpha-amylase mutants with predetermined properties |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5736499A (en) * | 1995-06-06 | 1998-04-07 | Genencor International, Inc. | Mutant A-amylase |
-
1996
- 1996-12-09 CA CA2274806A patent/CA2274806C/en not_active Expired - Lifetime
- 1996-12-09 AU AU14614/97A patent/AU1461497A/en not_active Abandoned
- 1996-12-09 EP EP96945189A patent/EP0942994B1/en not_active Expired - Lifetime
- 1996-12-09 JP JP52659698A patent/JP4253041B2/en not_active Expired - Lifetime
- 1996-12-09 DE DE69634640T patent/DE69634640T2/en not_active Expired - Lifetime
- 1996-12-09 AT AT96945189T patent/ATE293696T1/en not_active IP Right Cessation
- 1996-12-09 WO PCT/US1996/019595 patent/WO1998026078A1/en not_active Ceased
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1995010603A1 (en) * | 1993-10-08 | 1995-04-20 | Novo Nordisk A/S | Amylase variants |
| WO1995035382A2 (en) * | 1994-06-17 | 1995-12-28 | Genecor International Inc. | NOVEL AMYLOLYTIC ENZYMES DERIVED FROM THE B. LICHENIFORMIS α-AMYLASE, HAVING IMPROVED CHARACTERISTICS |
| WO1996023874A1 (en) * | 1995-02-03 | 1996-08-08 | Novo Nordisk A/S | A method of designing alpha-amylase mutants with predetermined properties |
Non-Patent Citations (1)
| Title |
|---|
| MAASSEN A: "COMPARISON OF TWO ALPHA AMYLASES FROM BACILLUS-AMYLOLIQUEFACIENS AND BACILLUS-LICHENIFORMIS", BIOMED BIOCHIM ACTA, 50 (2). 1991. 213-218., XP002039104 * |
Cited By (132)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8323946B2 (en) | 1995-02-03 | 2012-12-04 | Novozymes A/S | Alpha-amylase mutants |
| WO1999009183A1 (en) * | 1997-08-19 | 1999-02-25 | Genencor International, Inc. | MUTANT α-AMYLASE COMPRISING MODIFICATION AT RESIDUES CORRESPONDING TO A210, H405 AND/OR T412 IN $i(BACILLUS LICHENIFORMIS) |
| US7601527B2 (en) | 1998-11-16 | 2009-10-13 | Novozymes A/S | α-amylase variants |
| US8465957B2 (en) | 1998-11-16 | 2013-06-18 | Novozymes A/S | Alpha-amylase variants |
| EP1676913A3 (en) * | 1998-11-16 | 2007-08-29 | Novozymes A/S | Alpha-amylase variants |
| JP2011087582A (en) * | 1998-12-18 | 2011-05-06 | Danisco Us Inc | Novel variant egiii-like cellulase composition |
| US7867746B2 (en) | 1999-03-30 | 2011-01-11 | Novozymes A/S | Alpha-amylase variants |
| US8124395B2 (en) | 1999-03-30 | 2012-02-28 | Novozymes A/S | Alpha-amylase variants |
| EP1818396A3 (en) * | 1999-03-30 | 2007-12-19 | Novozymes A/S | Alpha-Amylase variants |
| US10113157B2 (en) | 1999-03-30 | 2018-10-30 | Novozymes A/S | Alpha-amylase variants |
| US9464279B2 (en) | 1999-03-30 | 2016-10-11 | Novozymes A/S | Alpha-amylase variants |
| EP2290060A1 (en) * | 1999-03-30 | 2011-03-02 | Novozymes A/S | Alpha-amylase variants |
| US8859255B2 (en) | 1999-03-30 | 2014-10-14 | Novozymes A/S | Alpha-amylase variants |
| US8420370B2 (en) | 1999-03-30 | 2013-04-16 | Novozymes A/S | Alpha-amylase variants |
| WO2000077193A1 (en) * | 1999-06-10 | 2000-12-21 | Rijksuniversiteit Groningen | Enzyme selection |
| JP2004500815A (en) * | 1999-12-23 | 2004-01-15 | ジェネンコア インターナショナル インコーポレーテッド | Methods for obtaining proteins with improved functional properties |
| WO2001047956A3 (en) * | 1999-12-23 | 2002-02-14 | Genencor Int | Method for obtaining proteins having improved functional characteristics |
| US7153818B2 (en) | 2000-07-28 | 2006-12-26 | Henkel Kgaa | Amylolytic enzyme extracted from bacillus sp. A 7-7 (DSM 12368) and washing and cleaning agents containing this novel amylolytic enzyme |
| US7713723B1 (en) | 2000-08-01 | 2010-05-11 | Novozymes A/S | Alpha-amylase mutants with altered properties |
| EP1597363B1 (en) * | 2003-02-26 | 2015-07-15 | Danisco US Inc. | Amylases producing an altered immunogenic response and methods of making and using the same |
| US8080401B2 (en) | 2004-10-01 | 2011-12-20 | Henkel Ag & Co. Kgaa | Alpha-amylase variants having an elevated solvent stability, method for the production thereof and detergents and cleansers containing these alpha-amylase variants |
| DE102004047777B4 (en) | 2004-10-01 | 2018-05-09 | Basf Se | Alpha-amylase variants with increased solvent stability, process for their preparation and their use |
| WO2007144856A3 (en) * | 2006-06-16 | 2008-07-24 | Procter & Gamble | Cleaning and / or treatment compositions comprising mutant alpha-amylases |
| US7629158B2 (en) | 2006-06-16 | 2009-12-08 | The Procter & Gamble Company | Cleaning and/or treatment compositions |
| WO2012004759A3 (en) * | 2010-07-08 | 2012-11-01 | Dupont Nutrition Biosciences Aps | Method for identifying a pepsin resistant alpha amylase |
| CN103119174A (en) * | 2010-07-08 | 2013-05-22 | 杜邦营养生物科学有限公司 | Method for identifying pepsin-resistant alpha-amylases |
| EP2591123B1 (en) | 2010-07-08 | 2016-10-05 | DuPont Nutrition Biosciences ApS | Method for identifying a pepsin resistant alpha amylase |
| AU2011275358B2 (en) * | 2010-07-08 | 2015-05-28 | International N&H Denmark Aps | Method for identifying a pepsin resistant alpha amylase |
| US10059750B2 (en) | 2013-03-15 | 2018-08-28 | Angelica Therapeutics, Inc. | Modified toxins |
| WO2014150600A3 (en) * | 2013-03-15 | 2015-05-28 | Angelica Therapeutics, Inc. | Modified toxins |
| WO2014194032A1 (en) | 2013-05-29 | 2014-12-04 | Danisco Us Inc. | Novel metalloproteases |
| EP3636662A1 (en) | 2013-05-29 | 2020-04-15 | Danisco US Inc. | Novel metalloproteases |
| EP3882346A1 (en) | 2013-05-29 | 2021-09-22 | Danisco US Inc. | Novel metalloproteases |
| WO2014194117A2 (en) | 2013-05-29 | 2014-12-04 | Danisco Us Inc. | Novel metalloproteases |
| WO2014194054A1 (en) | 2013-05-29 | 2014-12-04 | Danisco Us Inc. | Novel metalloproteases |
| WO2014194034A2 (en) | 2013-05-29 | 2014-12-04 | Danisco Us Inc. | Novel metalloproteases |
| EP4159854A1 (en) | 2013-05-29 | 2023-04-05 | Danisco US Inc | Novel metalloproteases |
| EP3260538A1 (en) | 2013-05-29 | 2017-12-27 | Danisco US Inc. | Novel metalloproteases |
| EP3553173A1 (en) | 2013-12-13 | 2019-10-16 | Danisco US Inc. | Serine proteases of the bacillus gibsonii-clade |
| WO2015089447A1 (en) | 2013-12-13 | 2015-06-18 | Danisco Us Inc. | Serine proteases of the bacillus gibsonii-clade |
| WO2015089441A1 (en) | 2013-12-13 | 2015-06-18 | Danisco Us Inc. | Serine proteases of bacillus species |
| EP3514230A1 (en) | 2013-12-13 | 2019-07-24 | Danisco US Inc. | Serine proteases of bacillus species |
| EP3910057A1 (en) | 2013-12-13 | 2021-11-17 | Danisco US Inc. | Serine proteases of the bacillus gibsonii-clade |
| EP4163305A1 (en) | 2013-12-16 | 2023-04-12 | Nutrition & Biosciences USA 4, Inc. | Use of poly alpha-1,3-glucan ethers as viscosity modifiers |
| EP3789407A1 (en) | 2013-12-18 | 2021-03-10 | Nutrition & Biosciences USA 4, Inc. | Cationic poly alpha-1,3-glucan ethers |
| WO2015095358A1 (en) | 2013-12-18 | 2015-06-25 | E. I. Du Pont De Nemours And Company | Cationic poly alpha-1,3-glucan ethers |
| WO2015123323A1 (en) | 2014-02-14 | 2015-08-20 | E. I. Du Pont De Nemours And Company | Poly-alpha-1,3-1,6-glucans for viscosity modification |
| WO2015138283A1 (en) | 2014-03-11 | 2015-09-17 | E. I. Du Pont De Nemours And Company | Oxidized poly alpha-1,3-glucan as detergent builder |
| EP4155398A1 (en) | 2014-03-21 | 2023-03-29 | Danisco US Inc. | Serine proteases of bacillus species |
| EP3587569A1 (en) | 2014-03-21 | 2020-01-01 | Danisco US Inc. | Serine proteases of bacillus species |
| EP3919599A1 (en) | 2014-06-19 | 2021-12-08 | Nutrition & Biosciences USA 4, Inc. | Compositions containing one or more poly alpha-1,3-glucan ether compounds |
| WO2015195777A1 (en) | 2014-06-19 | 2015-12-23 | E. I. Du Pont De Nemours And Company | Compositions containing one or more poly alpha-1,3-glucan ether compounds |
| WO2015195960A1 (en) | 2014-06-19 | 2015-12-23 | E. I. Du Pont De Nemours And Company | Compositions containing one or more poly alpha-1,3-glucan ether compounds |
| WO2016061438A1 (en) | 2014-10-17 | 2016-04-21 | Danisco Us Inc. | Serine proteases of bacillus species |
| WO2016069557A1 (en) | 2014-10-27 | 2016-05-06 | Danisco Us Inc. | Serine proteases of bacillus species |
| WO2016069569A2 (en) | 2014-10-27 | 2016-05-06 | Danisco Us Inc. | Serine proteases |
| WO2016069552A1 (en) | 2014-10-27 | 2016-05-06 | Danisco Us Inc. | Serine proteases |
| EP3550017A1 (en) | 2014-10-27 | 2019-10-09 | Danisco US Inc. | Serine proteases |
| WO2016069544A1 (en) | 2014-10-27 | 2016-05-06 | Danisco Us Inc. | Serine proteases |
| WO2016069548A2 (en) | 2014-10-27 | 2016-05-06 | Danisco Us Inc. | Serine proteases |
| EP4403631A2 (en) | 2014-10-27 | 2024-07-24 | Danisco US Inc. | Serine proteases |
| WO2016106011A1 (en) | 2014-12-23 | 2016-06-30 | E. I. Du Pont De Nemours And Company | Enzymatically produced cellulose |
| EP3872174A1 (en) | 2015-05-13 | 2021-09-01 | Danisco US Inc. | Aprl-clade protease variants and uses thereof |
| EP4219704A2 (en) | 2015-05-13 | 2023-08-02 | Danisco US Inc | Aprl-clade protease variants and uses thereof |
| WO2016201044A1 (en) | 2015-06-09 | 2016-12-15 | Danisco Us Inc | Osmotic burst encapsulates |
| WO2016201069A1 (en) | 2015-06-09 | 2016-12-15 | Danisco Us Inc | Low-density enzyme-containing particles |
| WO2016201040A1 (en) | 2015-06-09 | 2016-12-15 | Danisco Us Inc. | Water-triggered enzyme suspension |
| WO2016205755A1 (en) | 2015-06-17 | 2016-12-22 | Danisco Us Inc. | Bacillus gibsonii-clade serine proteases |
| EP4234693A2 (en) | 2015-06-17 | 2023-08-30 | Danisco US Inc | Bacillus gibsonii-clade serine proteases |
| WO2017079751A1 (en) | 2015-11-05 | 2017-05-11 | Danisco Us Inc | Paenibacillus sp. mannanases |
| WO2017079756A1 (en) | 2015-11-05 | 2017-05-11 | Danisco Us Inc | Paenibacillus and bacillus spp. mannanases |
| EP4483721A2 (en) | 2015-11-05 | 2025-01-01 | Danisco US Inc. | Paenibacillus and bacillus spp. mannanases |
| EP4141113A1 (en) | 2015-11-05 | 2023-03-01 | Danisco US Inc | Paenibacillus sp. mannanases |
| US10822574B2 (en) | 2015-11-13 | 2020-11-03 | Dupont Industrial Biosciences Usa, Llc | Glucan fiber compositions for use in laundry care and fabric care |
| WO2017083226A1 (en) | 2015-11-13 | 2017-05-18 | E. I. Du Pont De Nemours And Company | Glucan fiber compositions for use in laundry care and fabric care |
| WO2017083229A1 (en) | 2015-11-13 | 2017-05-18 | E. I. Du Pont De Nemours And Company | Glucan fiber compositions for use in laundry care and fabric care |
| US10876074B2 (en) | 2015-11-13 | 2020-12-29 | Dupont Industrial Biosciences Usa, Llc | Glucan fiber compositions for use in laundry care and fabric care |
| US10844324B2 (en) | 2015-11-13 | 2020-11-24 | Dupont Industrial Biosciences Usa, Llc | Glucan fiber compositions for use in laundry care and fabric care |
| WO2017083228A1 (en) | 2015-11-13 | 2017-05-18 | E. I. Du Pont De Nemours And Company | Glucan fiber compositions for use in laundry care and fabric care |
| US12480110B2 (en) | 2015-12-09 | 2025-11-25 | Danisco Us Inc. | Alpha-amylase combinatorial variants |
| US11920170B2 (en) | 2015-12-09 | 2024-03-05 | Danisco Us Inc. | Alpha-amylase combinatorial variants |
| WO2017106676A1 (en) | 2015-12-18 | 2017-06-22 | Danisco Us Inc | Polypeptides with endoglucanase activity and uses thereof |
| WO2017192692A1 (en) | 2016-05-03 | 2017-11-09 | Danisco Us Inc | Protease variants and uses thereof |
| WO2017192300A1 (en) | 2016-05-05 | 2017-11-09 | Danisco Us Inc | Protease variants and uses thereof |
| EP3845642A1 (en) | 2016-05-05 | 2021-07-07 | Danisco US Inc. | Protease variants and uses thereof |
| WO2017210295A1 (en) | 2016-05-31 | 2017-12-07 | Danisco Us Inc. | Protease variants and uses thereof |
| EP4527923A2 (en) | 2016-06-17 | 2025-03-26 | Danisco US Inc | Protease variants and uses thereof |
| EP4151726A1 (en) | 2016-06-17 | 2023-03-22 | Danisco US Inc | Protease variants and uses thereof |
| WO2017219011A1 (en) | 2016-06-17 | 2017-12-21 | Danisco Us Inc | Protease variants and uses thereof |
| WO2018085524A2 (en) | 2016-11-07 | 2018-05-11 | Danisco Us Inc | Laundry detergent composition |
| WO2018112123A1 (en) | 2016-12-15 | 2018-06-21 | Danisco Us Inc. | Polypeptides with endoglucanase activity and uses thereof |
| EP4212622A2 (en) | 2016-12-21 | 2023-07-19 | Danisco US Inc. | Bacillus gibsonii-clade serine proteases |
| WO2018118917A1 (en) | 2016-12-21 | 2018-06-28 | Danisco Us Inc. | Protease variants and uses thereof |
| EP4424805A2 (en) | 2016-12-21 | 2024-09-04 | Danisco Us Inc | Bacillus gibsonii-clade serine proteases |
| WO2018118950A1 (en) | 2016-12-21 | 2018-06-28 | Danisco Us Inc. | Bacillus gibsonii-clade serine proteases |
| EP4520820A2 (en) | 2016-12-21 | 2025-03-12 | Danisco Us Inc | Protease variants and uses thereof |
| WO2018169750A1 (en) | 2017-03-15 | 2018-09-20 | Danisco Us Inc | Trypsin-like serine proteases and uses thereof |
| WO2018183662A1 (en) | 2017-03-31 | 2018-10-04 | Danisco Us Inc | Delayed release enzyme formulations for bleach-containing detergents |
| WO2019006077A1 (en) | 2017-06-30 | 2019-01-03 | Danisco Us Inc | Low-agglomeration, enzyme-containing particles |
| WO2019108599A1 (en) | 2017-11-29 | 2019-06-06 | Danisco Us Inc | Subtilisin variants having improved stability |
| WO2019125683A1 (en) | 2017-12-21 | 2019-06-27 | Danisco Us Inc | Enzyme-containing, hot-melt granules comprising a thermotolerant desiccant |
| WO2019156670A1 (en) | 2018-02-08 | 2019-08-15 | Danisco Us Inc. | Thermally-resistant wax matrix particles for enzyme encapsulation |
| WO2019245704A1 (en) | 2018-06-19 | 2019-12-26 | Danisco Us Inc | Subtilisin variants |
| WO2019245705A1 (en) | 2018-06-19 | 2019-12-26 | Danisco Us Inc | Subtilisin variants |
| WO2020047215A1 (en) | 2018-08-30 | 2020-03-05 | Danisco Us Inc | Enzyme-containing granules |
| WO2020068486A1 (en) | 2018-09-27 | 2020-04-02 | Danisco Us Inc | Compositions for medical instrument cleaning |
| WO2020112599A1 (en) | 2018-11-28 | 2020-06-04 | Danisco Us Inc | Subtilisin variants having improved stability |
| WO2020242858A1 (en) | 2019-05-24 | 2020-12-03 | Danisco Us Inc | Subtilisin variants and methods of use |
| WO2020247582A1 (en) | 2019-06-06 | 2020-12-10 | Danisco Us Inc | Methods and compositions for cleaning |
| WO2022047149A1 (en) | 2020-08-27 | 2022-03-03 | Danisco Us Inc | Enzymes and enzyme compositions for cleaning |
| WO2022165107A1 (en) | 2021-01-29 | 2022-08-04 | Danisco Us Inc | Compositions for cleaning and methods related thereto |
| WO2023278297A1 (en) | 2021-06-30 | 2023-01-05 | Danisco Us Inc | Variant lipases and uses thereof |
| WO2023034486A2 (en) | 2021-09-03 | 2023-03-09 | Danisco Us Inc. | Laundry compositions for cleaning |
| WO2023039270A2 (en) | 2021-09-13 | 2023-03-16 | Danisco Us Inc. | Bioactive-containing granules |
| WO2023114932A2 (en) | 2021-12-16 | 2023-06-22 | Danisco Us Inc. | Subtilisin variants and methods of use |
| WO2023114939A2 (en) | 2021-12-16 | 2023-06-22 | Danisco Us Inc. | Subtilisin variants and methods of use |
| WO2023114936A2 (en) | 2021-12-16 | 2023-06-22 | Danisco Us Inc. | Subtilisin variants and methods of use |
| WO2023168234A1 (en) | 2022-03-01 | 2023-09-07 | Danisco Us Inc. | Enzymes and enzyme compositions for cleaning |
| WO2023225459A2 (en) | 2022-05-14 | 2023-11-23 | Novozymes A/S | Compositions and methods for preventing, treating, supressing and/or eliminating phytopathogenic infestations and infections |
| WO2023250301A1 (en) | 2022-06-21 | 2023-12-28 | Danisco Us Inc. | Methods and compositions for cleaning comprising a polypeptide having thermolysin activity |
| WO2024050346A1 (en) | 2022-09-02 | 2024-03-07 | Danisco Us Inc. | Detergent compositions and methods related thereto |
| WO2024050343A1 (en) | 2022-09-02 | 2024-03-07 | Danisco Us Inc. | Subtilisin variants and methods related thereto |
| WO2024050339A1 (en) | 2022-09-02 | 2024-03-07 | Danisco Us Inc. | Mannanase variants and methods of use |
| WO2024102698A1 (en) | 2022-11-09 | 2024-05-16 | Danisco Us Inc. | Subtilisin variants and methods of use |
| WO2024163584A1 (en) | 2023-02-01 | 2024-08-08 | Danisco Us Inc. | Subtilisin variants and methods of use |
| WO2024186819A1 (en) | 2023-03-06 | 2024-09-12 | Danisco Us Inc. | Subtilisin variants and methods of use |
| WO2024191711A1 (en) | 2023-03-16 | 2024-09-19 | Nutrition & Biosciences USA 4, Inc. | Brevibacillus fermentate extracts for cleaning and malodor control and use thereof |
| WO2025071996A1 (en) | 2023-09-28 | 2025-04-03 | Danisco Us Inc. | Variant cutinase enzymes with improved solubility and uses thereof |
| WO2025085351A1 (en) | 2023-10-20 | 2025-04-24 | Danisco Us Inc. | Subtilisin variants and methods of use |
| WO2026024921A1 (en) | 2024-07-25 | 2026-01-29 | The Procter & Gamble Company | Detergent composition comprising a subtilisin variant and methods of use |
| WO2026024922A1 (en) | 2024-07-25 | 2026-01-29 | Danisco Us Inc. | Subtilisin variants and methods of use |
| WO2026050315A1 (en) | 2024-08-29 | 2026-03-05 | Danisco Us Inc. | Subtilisin variants and methods of use |
Also Published As
| Publication number | Publication date |
|---|---|
| EP0942994B1 (en) | 2005-04-20 |
| JP2001506496A (en) | 2001-05-22 |
| ATE293696T1 (en) | 2005-05-15 |
| JP4253041B2 (en) | 2009-04-08 |
| DE69634640D1 (en) | 2005-05-25 |
| CA2274806A1 (en) | 1998-06-18 |
| CA2274806C (en) | 2011-02-01 |
| DE69634640T2 (en) | 2006-01-19 |
| AU1461497A (en) | 1998-07-03 |
| EP0942994A1 (en) | 1999-09-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0942994B1 (en) | H mutant alpha-amylase enzymes | |
| EP1002098B1 (en) | Mutant alpha-amylase having introduced therein a disulfide bond | |
| EP1038007B1 (en) | Mutant bacillus licheniformis alpha-amylase | |
| EP0938570B1 (en) | Mutant alpha-amylase comprising modification at residues corresponding to a210, h405 and/or t412 in bacillus licheniformis | |
| CA2222726C (en) | Mutant .alpha.-amylase | |
| US5849549A (en) | Oxidatively stable alpha-amylase | |
| MXPA97009472A (en) | Alfa amilasa muta | |
| CA2394740C (en) | Method for obtaining proteins having improved functional characteristics | |
| NZ524303A (en) | Alpha amylase enzymes with increased stability | |
| AU2616302A (en) | H-mutant alpha-amylase enzymes | |
| MXPA99003634A (en) | MUTANT&agr;-AMYLASE COMPRISING MODIFICATION AT RESIDUES CORRESPONDING TO A210, H405 AND/OR T412 IN BACILLUS LICHENIFORMIS | |
| CN1242048A (en) | H mutant alpha-amylase | |
| MXPA00000384A (en) | MUTANT&agr;-AMYLASE HAVING INTRODUCED THEREIN A DISULFIDE BOND |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| WWE | Wipo information: entry into national phase |
Ref document number: 96180572.2 Country of ref document: CN |
|
| AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG UZ VN AM AZ BY KG KZ MD RU TJ TM |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML |
|
| DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| ENP | Entry into the national phase |
Ref document number: 2274806 Country of ref document: CA Ref document number: 2274806 Country of ref document: CA Kind code of ref document: A |
|
| WWE | Wipo information: entry into national phase |
Ref document number: PA/a/1999/005321 Country of ref document: MX |
|
| ENP | Entry into the national phase |
Ref document number: 1998 526596 Country of ref document: JP Kind code of ref document: A |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 1996945189 Country of ref document: EP |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 336673 Country of ref document: NZ |
|
| WWP | Wipo information: published in national office |
Ref document number: 1996945189 Country of ref document: EP |
|
| REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
| WWG | Wipo information: grant in national office |
Ref document number: 1996945189 Country of ref document: EP |
